Systemic Therapy for Atopic Dermatitis: Choosing Biologics or Janus Kinase Inhibitors for Children and Adults

Scholl IM, Drucker AM, Flohr C, Gerbens LAA.  J Allergy Clin Immunol Pract. 2026 Feb;14(2):344-359. doi: 10.1016/j.jaip.2025.10.052.

Abstract

Mechanism of action of biologics and Janus kinase (JAK) inhibitors

Atopic dermatitis is a highly prevalent chronic inflammatory skin disease worldwide, with a significant burden on patients’ quality of life. Although most patients with atopic dermatitis are effectively managed with topical treatments, a significant minority requires systemic therapy. In recent years, the therapeutic landscape for this patient population has expanded beyond conventional treatments, introducing novel targeted therapies such as biologic agents and Janus kinase inhibitors.

These novel therapies vary in aspects such as efficacy, safety profile, route of administration, monitoring requirements, and impact on comorbidities, necessitating individualized treatment decision-making. As a result, selecting the most appropriate therapy can be challenging. This article provides a practical overview of the current targeted therapies to support informed clinical decision-making regarding treatment selection, monitoring, and dosing considerations.

PDF